Overview

CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension

Status:
Completed

Trial end date:
2019-07-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine if intravenous CD101 is safe and effective in the treatment of candidemia and/or invasive candidiasis when compared to caspofungin (followed by oral fluconazole).

Phase:

Phase 2

Details

Lead Sponsor:

Cidara Therapeutics Inc.

Treatments:

Caspofungin
Echinocandins
Fluconazole
Rezafungin